Galmed Pharmaceuticals (GLMD) Announces Proposed Offering of Ordinary Shares

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that it is commencing an underwritten public offering of its Ordinary Shares (the "Offering"). All of the shares to be sold in the Offering will be sold by Galmed, subject to customary closing conditions. In addition, Galmed intends to grant the underwriter for the Offering a 30-day option to purchase up to an additional 15% of the number of its Ordinary Shares offered in the public offering.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the Offering.

The Offering is being made pursuant to a "shelf" registration statement on Form F-3 (File No. 333-223923) previously filed by Galmed with the Securities and Exchange Commission (the "SEC") on March 26, 2018 and declared effective by the SEC on April 2, 2018.

You May Also Be Interested In

• Esquire Financial (ESQ) Files $100M Mixed Shelf
• Serve Robotics (SBOT) Prices 10M Share Offering at $4/sh, Uplists to Nasdaq
• Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh